フォロー
JG Kenna
JG Kenna
Pharmaceutical Director
確認したメール アドレス: safermedicines.org
タイトル
引用先
引用先
Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism …
NJ Hewitt, MJ Gómez Lechón, JB Houston, D Hallifax, HS Brown, ...
Drug metabolism reviews 39 (1), 159-234, 2007
8442007
Managing the challenge of chemically reactive metabolites in drug development
BK Park, A Boobis, S Clarke, CEP Goldring, D Jones, JG Kenna, ...
Nature Reviews Drug Discovery 10 (4), 292-306, 2011
4852011
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans
S Dawson, S Stahl, N Paul, J Barber, JG Kenna
Drug Metabolism and Disposition 40 (1), 130-138, 2012
3402012
Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group …
JG Kenna, H Satoh, DD Christ, LR Pohl
Journal of Pharmacology and Experimental Therapeutics 245 (3), 1103-1109, 1988
2771988
The immunologic and metabolic basis of drug hypersensitivities
LR Pohl, H Satoh, DD Christ, JG Kenna
Annual review of pharmacology and toxicology 28 (1), 367-387, 1988
2751988
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity
GP Aithal, L Ramsay, AK Daly, N Sonchit, JBS Leathart, G Alexander, ...
Hepatology 39 (5), 1430-1440, 2004
2582004
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human
TB Andersson, KP Kanebratt, JG Kenna
Expert opinion on drug metabolism & toxicology 8 (7), 909-920, 2012
2562012
The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys …
JM Hourihan, JG Kenna, JD Hayes
Antioxidants & redox signaling 19 (5), 465-481, 2013
2402013
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
RA Thompson, EM Isin, Y Li, L Weidolf, K Page, I Wilson, S Swallow, ...
Chemical research in toxicology 25 (8), 1616-1632, 2012
2332012
Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
E Eliasson, JG Kenna
Molecular pharmacology 50 (3), 573-582, 1996
2051996
Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.
H Satoh, BM Martin, AH Schulick, DD Christ, JG Kenna, LR Pohl
Proceedings of the National Academy of Sciences 86 (1), 322-326, 1989
2011989
Methods for reducing non-specific antibody binding in enzyme-linked immunosorbent assays
JG Kenna, GN Major, RS Williams
Journal of immunological methods 85 (2), 409-419, 1985
2001985
The organ toxicity of inhaled anesthetics
JG Kenna, RM Jones
Anesthesia & Analgesia 81 (6S), 51S-66S, 1995
1861995
Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis.
DD Christ, JG Kenna, W Kammerer, H Satoh, LR Pohl
Anesthesiology 69 (6), 833-838, 1988
1331988
Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis
GJ Kenna, J Neuberger, R Williams
Hepatology 8 (6), 1635-1641, 1988
1281988
Neoantigens associated with halothane hepatitis
LR Pohl, JG Kenna, H Satoh, D Christ, JL Martin
Drug metabolism reviews 20 (2-4), 203-217, 1989
1241989
Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane.
DD Christ, H Satoh, JG Kenna, LR Pohl
Drug Metabolism and Disposition 16 (1), 135-140, 1988
1201988
Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated …
JG Kenna, J Neuberger, R Williams
Journal of Pharmacology and Experimental Therapeutics 242 (2), 733-740, 1987
1181987
Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
RA Thompson, EM Isin, Y Li, R Weaver, L Weidolf, I Wilson, A Claesson, ...
Chemico-biological interactions 192 (1-2), 65-71, 2011
992011
Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase
JL Martin, GJ Kenna, BM Martin, D Thomassen, GF Reed, LR Pohl
Hepatology 18 (4), 858-863, 1993
961993
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20